HSBC Holdings
TRDA icon

HSBC Holdings’s Entrada Therapeutics TRDA Stock Holding History

HSBC Holdings’s Portfolio TRDA Stock Details TRDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$472K Buy
38,137
+17,304
+83% +$198K ﹤0.01% 2246
2025
Q4 		$216K Buy
20,833
+194
+0.9% +$1.64K ﹤0.01% 2664
2025
Q3 		$117K Buy
+20,639
New +$121K ﹤0.01% 2578

Other funds holding TRDA

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
MC
Merck & Co Kenilworth, New Jersey $349M AUM 146.07% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
SG
StepStone Group La Jolla, California $207M AUM 12.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

HSBC Holdings's TRDA Position: Q1 2026 in Review

HSBC Holdings increased its Entrada Therapeutics (TRDA) stake by 83% in Q1 2026, buying an estimated $198K and bringing the position to 38,137 shares worth $472K. The position accounts for ﹤0.01% of the portfolio, ranked #2246.

HSBC Holdings first reported a position in TRDA in Q3 2025 and has held it in 3 quarters since. 120 funds tracked by Wall St. Rank hold TRDA as of Q1 2026.

  • HSBC Holdings held 38,137 shares of Entrada Therapeutics worth $472K as of Q1 2026.
  • HSBC Holdings bought 17,304 Entrada Therapeutics shares in Q1 2026, an estimated $198K.
  • Entrada Therapeutics made up ﹤0.01% of HSBC Holdings's portfolio in Q1 2026, its #2246 holding.
  • HSBC Holdings first reported a position in Entrada Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • 120 funds tracked by Wall St. Rank held Entrada Therapeutics as of Q1 2026.

Based on HSBC Holdings's 13F filing for Q1 2026, filed 30 Apr 2026.